WALTHAM, Mass., July 1, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on June 28, 2022, the compensation committee of the company's board of directors granted six new non-executive employees options to purchase an aggregate of 332,483 shares of the company's common stock, and granted an aggregate of 83,375 Restricted Stock Units (RSUs) to eight new non-executive employees. Each stock option has an exercise price per share equal to $0.57 per share, which was the closing trading price of the company's common stock on the date of grant. The stock options and RSUs were granted as inducements material to each employee's decision to enter into employment with Ardelyx, in accordance with Nasdaq Listing Rule 5635(c)(4).
Read more at prnewswire.comArdelyx, Inc. Reports Employment Inducement Grants
Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
